72 related articles for article (PubMed ID: 12012010)
21. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
[TBL] [Abstract][Full Text] [Related]
23. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
J Biol Regul Homeost Agents; 1993; 7(4):121-5. PubMed ID: 8023699
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
[TBL] [Abstract][Full Text] [Related]
25. [Immunotherapy in radical surgery of colorectal carcinoma].
Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
28. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
Tsimberidou AM; Giles F; Romaguera J; Duvic M; Kurzrock R
Cancer; 2004 Feb; 100(3):574-80. PubMed ID: 14745875
[TBL] [Abstract][Full Text] [Related]
29. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Recchia F; Di Orio F; Candeloro G; Guerriero G; Piazze J; Rea S
Gynecol Oncol; 2010 Feb; 116(2):202-7. PubMed ID: 19880164
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
31. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H
Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
34. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients.
Romano F; Cesana G; Caprotti R; Bovo G; Uggeri F; Piacentini MG; Crippa S; Uggeri F
Hepatogastroenterology; 2006; 53(70):634-8. PubMed ID: 16995478
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
Tímár J; Ladányi A; Forster-Horváth C; Lukits J; Döme B; Remenár E; Godény M; Kásler M; Bencsik B; Répássy G; Szabó G; Velich N; Suba Z; Elo J; Balatoni Z; Pócza K; Zemplén B; Chretien P; Talor E
J Clin Oncol; 2005 May; 23(15):3421-32. PubMed ID: 15908653
[TBL] [Abstract][Full Text] [Related]
36. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer.
Recchia F; Saggio G; Cesta A; Candeloro G; Di Blasio A; Amiconi G; Lombardo M; Nuzzo A; Lalli A; Alesse E; Necozione S; Rea S
Cancer Immunol Immunother; 2007 May; 56(5):699-708. PubMed ID: 16955297
[TBL] [Abstract][Full Text] [Related]
38. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
Mantovani G; Madeddu C; Gramignano G; Lusso MR; Mocci M; Massa E; Ferreli L; Astara G; Macciò A; Serpe R
J Exp Ther Oncol; 2003; 3(4):205-19. PubMed ID: 14567291
[TBL] [Abstract][Full Text] [Related]
40. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.
Recchia F; Saggio G; Nuzzo A; Biondi E; Di Blasio A; Cesta A; Candeloro G; Alesse E; Rea S
J Immunother; 2006; 29(1):87-94. PubMed ID: 16365604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
